Percutaneous coronary interventions with the Absorb Bioresorbable vascular scaffold in real life 1-year results from the FRANCE ABSORB registry - Archive ouverte HAL Access content directly
Journal Articles Archives of cardiovascular diseases Year : 2019

Percutaneous coronary interventions with the Absorb Bioresorbable vascular scaffold in real life 1-year results from the FRANCE ABSORB registry

(1, 2, 3) , (4) , (5) , (6) , (7, 7) , (8) , (9) , (10, 11) , (12) , (13) , (14, 11) , (15) , , (16) , (17, 18, 19)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

Abstract

Background - Several randomized studies have shown that bioresorbable vascular scaffold (BVS) technology is associated with an increased risk of stent thrombosis. Aim - This study aimed to assess the rates of adverse outcomes at 1 year in patients treated with the Absorb BVS (Abbott Vascular, Santa Clara, CA, USA), using data from a large nationwide prospective multicentre registry (FRANCE ABSORB). Methods - All patients receiving the Absorb BVS in France were included prospectively in the study. Predilatation, optimal sizing and postdilatation were recommended systematically. The primary endpoint was a composite of cardiovascular death, myocardial infarction and target lesion revascularization at 1 year. Secondary endpoints were scaffold thrombosis and target vessel revascularization at 1 year. Results - A total of 2072 patients at 86 centres were included: mean age 55±11 years; 80% men. The indication was acute coronary syndrome (ACS) in 49% of cases. Predilatation and postdilatation were done in 93% and 83% of lesions, respectively. At 1 year, the primary endpoint occurred in 3.9% of patients, the rate of scaffold thrombosis was 1.5% and the rate of target vessel revascularization was 3.3%. In a multivariable analysis, diabetes and total Absorb BVS length>30mm were independently associated with the occurrence of the primary endpoint, whereas oral anticoagulation and total Absorb BVS length>30mm were independently associated with occurrence of scaffold thrombosis. Conclusions - The Absorb BVS was implanted in a relatively young population, half of whom had ACS. Predilatation and postdilatation rates were high, and 1-year outcomes were acceptable.
Fichier principal
Vignette du fichier
S1875213618301918.pdf (221.02 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-01998544 , version 1 (22-10-2021)

Licence

Attribution - NonCommercial - CC BY 4.0

Identifiers

Cite

Guillaume Cayla, René Koning, Jean Fajadet, Joel Sainsous, Didier Carrié, et al.. Percutaneous coronary interventions with the Absorb Bioresorbable vascular scaffold in real life 1-year results from the FRANCE ABSORB registry. Archives of cardiovascular diseases, 2019, 112 (2), pp.113-123. ⟨10.1016/j.acvd.2018.09.007⟩. ⟨hal-01998544⟩
78 View
19 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More